REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.
This following video is from Nicola Sturgeon, First Minister of Scotland's YouTube channel:
New headquarters strengthen drug discovery services and translational research, and generate new employment opportunities in Scotland. Press release 10th August 2017.
Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.
Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.
Proteon Therapeutics Inc. (Nasdaq:PRTO), a longstanding client of Biopta, is developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. Proteon today announced publication of additional nonclinical data on investigational drug vonapanitase in peripheral artery disease (PAD). The ex vivo study demonstrated that a single treatment of vonapanitase following angioplasty of excised atherosclerotic human tibial arteries altered artery compliance. Increased compliance is known to correlate with arterial dilation.
The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta. The acquisition of Biopta and its US subsidiary, Biopta Inc. is expected to complete on the 10th of December 2015 and is aimed at strengthening REPROCELL’s pharmaceutical industry-targeted drug discovery services. The acquisition will also see an immediate investment to expand Biopta’s range of contract research services. Biopta, which will continue to operate from its headquarters in Glasgow, aims to grow its workforce to 30 over the next three years and Biopta’s management views the synergies within the REPROCELL Group of companies as key to its growth ambitions.
The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society. This abstract describes the biological mechanisms by which a novel chemokine antagonist, AXP1275, impacts lung inflammation through its action at the CCR3-muscarinic M3 receptor heterodimer. The disease relevance of such biological complexity can only be truly demonstrated in fresh human tissue, in an environment where the receptor and pathway interaction occurs naturally.
Biopta's CEO publishes a review of functional human tissue assays in a new book entitled "Human-based systems for translational research", edited by Dr Robert Coleman and published by the Royal Society of Chemistry.
A new paper in the Journal of Cardiovascular Pharmacology describes a potential treatment for atherosclerosis. Proteon Therapeutics, Waltham, MA, has developed a recombinant pancreatic elastase that was tested for its ability to dilate atherosclerotic human arteries, ethically obtained from patients with peripheral artery disease and set up at Biopta's human tissue research facility in Scotland.
Biopta Ltd, the human tissue-based contract research organisation, today announced a major development in discovery research with the launch of the first catalog of assays based on human functional tissues. The catalogue serves to provide the scientific community with ready access to assays that improve the prediction of safety, absorption and efficacy of drug candidates in humans.
Sign up to receive information from REPROCELL about our products, services, applications, promotions, and news (includes a weekly blog update email).